FDA reviewers recommend against approval for Novartis heart failure drug
Ahead of an important advisory panel FDA reviewers have recommended against approval of a novel drug for acute heart failure from Novartis. The once highly-promising drug, which received a "breakthrough therapy" designation from the FDA last year, was turned down for approval in Europe earlier this year.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063